Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients

被引:3
作者
He, Jingjing [1 ]
Guo, Yifei [1 ]
Zhang, Yao [1 ]
Han, Jiajia [1 ]
Chen, Jingwen [1 ]
Jia, Yidi [1 ]
Ma, Zhenxuan [1 ]
Wu, Jingwen [1 ]
Zhang, Shenyan [1 ]
Li, Fahong [1 ]
Mao, Richeng [1 ,2 ]
Zhang, Jiming [1 ,2 ]
机构
[1] Fudan Univ, Huashan Hosp, Shanghai Inst Infect Dis & Biosecur, Natl Med Ctr Infect Dis,Dept Infect Dis,Shanghai K, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Shanghai Inst Infect Dis & Biosecur, Natl Med Ctr Infect Dis,Dept Infect Dis,Shanghai K, Room 510,Bldg 5,12 Middle Wulumuqi Rd, Shanghai, Peoples R China
来源
INFECTION AND DRUG RESISTANCE | 2023年 / 16卷
基金
中国国家自然科学基金;
关键词
hepatitis B virus infection; tenofovir alafenamide fumarate; tenofovir disoproxil fumarate; interferon; functional cure; combination therapy; PEGINTERFERON ALPHA-2B; NAIVE PATIENTS; MONOTHERAPY; ENTECAVIR;
D O I
10.2147/IDR.S411183
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: The study aims to evaluate the effectiveness of a tenofovir alafenamide fumarate (TAF) and pegylated interferon alfa (PegIFN-& alpha;) regimen compared to a tenofovir disoproxil fumarate (TDF) and PegIFN-& alpha; therapy in patients with chronic hepatitis B (CHB).Patients and Methods: Patients who were treated with PegIFN-& alpha; in combination with TAF or TDF were retrospectively enrolled. The primary outcome measured was the HBsAg loss rate. The rates of virological response, serological response for HBeAg, and normalization of alanine aminotransferase (ALT) were also calculated. The cumulative incidences of response rates were compared between the two groups using Kaplan-Meier analysis.Results: A total of 114 patients were retrospectively enrolled in the study, with 33 receiving TAF plus PegIFN-& alpha; treatment and 81 receiving TDF plus PegIFN-& alpha; treatment. The HBsAg loss rate for the TAF plus PegIFN-& alpha; group was 15.2% at 24 weeks and 21.2% at 48 weeks, while the TDF plus PegIFN-& alpha; group had rates of 7.4% at 24 weeks and 12.3% at 48 weeks (P=0.204 at 24 weeks, P=0.228 at 48 weeks). In subgroup analysis of HBeAg positive patients, the TAF group had a higher HBsAg loss rate of 25% at week 48, compared to 3.8% in the TDF group (P=0.033). According to Kaplan-Meier analysis, the TAF plus PegIFN-& alpha; group achieved virological response more quickly than the TDF plus PegIFN-& alpha; group (p=0.013). There was no statistical difference in HBeAg serological rate or ALT normalization rate. Conclusion: There was no significant difference in the HBsAg loss between the two groups. However, subgroup analysis revealed that TAF plus PegIFN-& alpha; treatment had a higher HBsAg loss rate than TDF plus PegIFN-& alpha; treatment in HBeAg-positive patients. Additionally, TAF plus PegIFN-& alpha; treatment demonstrated better virological suppression for CHB patients. Therefore, TAF plus PegIFN-& alpha; treatment regimen is recommended for CHB patients who aim to achieve functional cure.
引用
收藏
页码:3929 / 3941
页数:13
相关论文
共 39 条
[1]   96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection [J].
Agarwal, Kosh ;
Brunetto, Maurizia ;
Seto, Wai Kay ;
Lim, Young-Suk ;
Fung, Scott ;
Marcellin, Patrick ;
Ahn, Sang Hoon ;
Izumi, Namiki ;
Chuang, Wan-Long ;
Bae, Ho ;
Sharma, Manoj ;
Janssen, Harry L. A. ;
Pan, Calvin Q. ;
Celen, Mustafa Kemal ;
Furusyo, Norihiro ;
Shalimar, Dr ;
Yoon, Ki Tae ;
Huy Trinh ;
Flaherty, John F. ;
Gaggar, Anuj ;
Lau, Audrey H. ;
Cathcart, Andrea L. ;
Lin, Lanjia ;
Bhardwaj, Neeru ;
Suri, Vithika ;
Subramanian, G. Mani ;
Gane, Edward J. ;
Buti, Maria ;
Chan, Henry L. Y. .
JOURNAL OF HEPATOLOGY, 2018, 68 (04) :672-681
[2]   Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis [J].
Ahn, Sang Hoon ;
Marcellin, Patrick ;
Ma, Xiaoli ;
Caruntu, Florin A. ;
Tak, Won Young ;
Elkhashab, Magdy ;
Chuang, Wan-Long ;
Tabak, Fehmi ;
Mehta, Rajiv ;
Petersen, Joerg ;
Guyer, William ;
Jump, Belinda ;
Chan, Alain ;
Subramanian, Mani ;
Crans, Gerald ;
Fung, Scott ;
Buti, Maria ;
Gaeta, Giovanni B. ;
Hui, Aric J. ;
Papatheodoridis, George ;
Flisiak, Robert ;
Chan, Henry L. Y. .
DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (12) :3487-3497
[3]   Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis [J].
Buster, Erik H. C. J. ;
Hansen, Bettina E. ;
Buti, Maria ;
Delwaide, Jean ;
Niederau, Claus ;
Michielsen, Peter P. ;
Flisiak, Robert ;
Zondervan, Pieter E. ;
Schalm, Solko W. ;
Janssen, Harry L. A. .
HEPATOLOGY, 2007, 46 (02) :388-394
[4]   Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection [J].
Buti, Maria ;
Riveiro-Barciela, Mar ;
Esteban, Rafael .
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 :S792-S796
[5]   Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate [J].
Byun, Kwan Soo ;
Choi, Jonggi ;
Kim, Ji-Hoon ;
Lee, Yung Sang ;
Lee, Han Chu ;
Kim, Yoon Jun ;
Yoo, Byung Chul ;
Kwon, So Young ;
Gwak, Geum-Youn ;
Lim, Young-Suk .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) :427-437
[6]   Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial [J].
Cheng, Jun ;
Wang, Yuming ;
Hou, Jinlin ;
Luo, Duande ;
Xie, Qing ;
Ning, Qin ;
Ren, Hong ;
Ding, Huiguo ;
Sheng, Jifang ;
Wei, Lai ;
Chen, Shijun ;
Fan, Xiaoling ;
Huang, Wenxiang ;
Pan, Chen ;
Gao, Zhiliang ;
Zhang, Jiming ;
Zhou, Boping ;
Chen, Guofeng ;
Wan, Mobin ;
Tang, Hong ;
Wang, Guiqiang ;
Yang, Yuxiu ;
Mohamed, Rosmawati ;
Guan, Richard ;
Lee, Tzong-Hsi ;
Chang, Wen-Hsiung ;
Huang Zhenfei ;
Ye, Zhang ;
Xu, Daozhen .
JOURNAL OF CLINICAL VIROLOGY, 2014, 61 (04) :509-516
[7]  
Chinese Society of Infectious Diseases Chinese Medical Association, 2019, Zhonghua Gan Zang Bing Za Zhi, V27, P938, DOI 10.3760/cma.j.issn.1007-3418.2019.12.007
[8]   An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) TRACES Study [J].
Chon, Young Eun ;
Kim, Dong Joon ;
Kim, Sang Gyune ;
Kim, In Hee ;
Bae, Si Hyun ;
Hwang, Seong Gyu ;
Heo, Jeong ;
Jang, Jeong Won ;
Lee, Byung Seok ;
Kim, Hyung Joon ;
Jun, Dae Won ;
Kim, Kang Mo ;
Chung, Woo Jin ;
Choi, Moon Seok ;
Jang, Jae Young ;
Yim, Hyung Joon ;
Tak, Won Young ;
Yoon, Ki Tae ;
Park, Jun Yong ;
Han, Kwang-Hyub ;
Suk, Ki Tae ;
Lee, Hyun Woong ;
Jang, Byoung Kuk ;
Ahn, Sang Hoon .
MEDICINE, 2016, 95 (14)
[9]   Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials [J].
De Ridder, Filip ;
Sonneveld, Milan J. ;
Lenz, Oliver ;
Janssen, Harry L. A. ;
Talloen, Willem ;
Hansen, Bettina E. .
JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) :1563-1569
[10]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398